Satellos Bioscience (TSE:MSCL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Satellos Bioscience successfully closed a $40 million public offering, issuing over 63 million equity securities, to fund its Phase 2 clinical program for SAT-3247. The offering was led by Bloom Burton Securities Inc. and participated by several agents. The funds will support clinical development and general corporate needs.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.